Author pages are created from data sourced from our academic publisher partnerships and public sources.
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study
BackgroundThe 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination… Expand
Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer
5072 Background: Pegylated liposomal doxorubicin ( PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limit...
The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.
- U. Ortmann, J. Salmen, +7 authors W. Janni
- Journal of clinical oncology : official journal…
- 20 May 2011
1070 Background: Taxane-based anthracycline containing chemotherapy has been established as treatment option in the adjuvant setting of early breast cancer. Indication was recently enlarged for high… Expand
Sequential therapy with carboplatin (C) followed by paclitaxel (P) as first-line chemotherapy in 105 patients with advanced ovarian cancer (AOC): Results of a multicenter phase II study of the…
5533 Background: For the adjuvant setting of AOC after primary radical surgery the combination of paclitaxel and platinum in a three weeks schedule has emerged as the current standard. Exposition d...
- G. Oskav-Özcelik, H. Hindenburg, +214 authors Ş. Zeteroğlu
- Archives of Gynecology and Obstetrics
OBJECTIVES: Caelyx is a novel pegylated liposomal doxorubicin formulation and has been approved for the treatment of recurrent ovarian cancer. METHODS: We performed a multi-institutional phase-II… Expand
How office based gyneco-oncologists in Germany apply antiemetic guidelines in patients receiving AC-containing (neo) adjuvant chemotherapy.